Zealand Pharma A/S (ZEAL)
| Market Cap | 1.44B |
| Revenue (ttm) | 5.82M |
| Net Income (ttm) | 89.15M |
| Shares Out | 43.39M |
| EPS (ttm) | -3.72 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | June 18 |
| Last Price | $30.83 |
| Previous Close | $31.02 |
| Change ($) | -0.19 |
| Change (%) | -0.60% |
| Day's Open | 31.25 |
| Day's Range | 30.83 - 31.32 |
| Day's Volume | 61,672 |
| 52-Week Range | 27.90 - 44.42 |
C ompany a nnouncement – No. 39/ 202 1
Company announcement – No. 38 / 20 2 1
Company announcement – No. 37 / 20 2 1
C ompany a nnouncement – No. 36 / 202 1
C ompany a nnouncement – No. 35 / 202 1
Company announcement – No. 34 / 20 2 1
Company announcement – No. 33 / 20 2 1
C ompany a nnouncement – No. 32 / 202 1
Company announcement – No. 31/ 20 2 1
Zealand Pharma AS (ZEAL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
C ompany a nnouncement – No. 29 / 202 1
Company announcement – No. 28 / 20 2 1
C ompany a nnouncement – No. 27 / 202 1
Company announcement – No. 26 / 20 2 1
C ompany a nnouncement – No. 25 / 202 1
Company announcement – No. 23 / 20 2 1
Company announcement – No. 22 / 2021
Company announcement – No. 21/ 2021
A new, easier-to-administer treatment for severe hypoglycemia has observers and investors wondering where its creators will go next.
Company announcement – No. 19/ 2021
Company announcement – No. 18/ 2021
Company announcement – No. 17 / 2020
Company announcement – No. 16 / 2021
Biotech stocks reversed course in the week ended March 19 amid mixed news flow on data readouts and lackluster broader market performance. Rubius Therapeutics, Inc. (NASDAQ: RUBY) was among the biggest ...
Company announcement – No. 14 / 2021
Company Announcement – No. 13 / 2021
Company announcement – No. 12 / 2021
Company announcement – No. 11/ 2021
Company announcement – No. 10 / 2021
Company announcement – No. 9 / 2021
Press Release – No. 7 / 2021
Company announcement – No. 4 / 2021
Company announcement – No. 3 / 2021
Company announcement – No. 2 / 2021
Company announcement – No. 1 / 2021
Company announcement – No. 64 / 2020
Company announcement – No. 63 / 2020
Company announcement – No. 62 / 2020
Company announcement – No. 61 / 2020
Company announcement – No. 60 / 2020
Company announcement – No. 59 / 2020
Company announcement – No. 58 / 2020
Company announcement – No. 57 / 2020
In this article we will take a look at whether hedge funds think Zealand Pharma A/S (NASDAQ:ZEAL) is a good investment right now. We check hedge fund and billionaire investor sentiment before delving in...
Company announcement – No. 56 / 2020
Company announcement – No. 55 / 2020
Zealand Pharma A/S (ZLDPF) CEO Emmanuel Dulac on Q3 2020 Results - Earnings Call Transcript
Zealand Pharma A/S (ZEAL) CEO Emmanuel Dulac on Q3 2020 Results - Earnings Call Transcript
About ZEAL
Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin, Lyxumia, Soliqua 100/33, and Suliqua. Its product pipeline includes Dasiglucagon single use syringe or autoinjector that has completed Phase III clinical trials for the treatment of severe hypoglycemia; D... [Read more...]
| Industry Biotechnology | IPO Date Aug 9, 2017 |
| CEO Emmanuel Dulac | Employees 335 |
| Stock Exchange NASDAQ | Ticker Symbol ZEAL |
Analyst Forecasts
According to 4 analysts, the average rating for ZEAL stock is "Buy." The 12-month stock price forecast is 38.61, which is an increase of 25.24% from the latest price.